By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Loxo Oncology 

1 Landmark Square
Suite 1122
Stamford  Connecticut  06901  U.S.A.
Phone: 203-653-3880 Fax: n/a


Company News
Loxo Oncology (LOXO) Announces The Closing Of Its Follow-On Offering Of Common Stock And Full Exercise Of The Underwriters’ Option To Purchase Additional Shares 6/21/2017 10:40:04 AM
Loxo Oncology (LOXO) Prices Follow-On Offering Of Common Stock 6/15/2017 12:48:55 PM
Loxo Oncology (LOXO) Announces Clinical Proof Of Concept Publication For Next-Generation TRK Inhibitor LOXO-195 6/5/2017 12:42:10 PM
Loxo Oncology (LOXO) Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It 6/5/2017 5:49:41 AM
Loxo Oncology (LOXO) Announces FDA Clearance Of Investigational New Drug (IND) Application For Next-Generation TRK Inhibitor, LOXO-195 5/30/2017 11:17:44 AM
Loxo Oncology (LOXO) Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 ASCO Annual Meeting 5/18/2017 11:18:09 AM
Loxo Oncology (LOXO) Announces FDA Orphan Drug Designation Granted To Larotrectinib For The Treatment Of Solid Tumors With NTRK-Fusion Proteins 5/12/2017 8:49:46 AM
Loxo Oncology (LOXO) Announces Enrollment Of First Patient In Phase I Clinical Trial For Highly Selective RET Inhibitor, LOXO-292 5/10/2017 10:19:14 AM
Loxo Oncology (LOXO) Announces First Quarter 2017 Financial Results 5/9/2017 10:29:38 AM
Loxo Oncology (LOXO) To Announce First Quarter 2017 Financial Results 5/2/2017 10:46:02 AM